News
Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...
Roche's Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulat
